Prenetics Global Limited (NASDAQ:PRE) Given Average Rating of “Moderate Buy” by Brokerages

Prenetics Global Limited (NASDAQ:PRE – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $34.80.

A number of equities research analysts have commented on PRE shares. B. Riley Financial initiated coverage on shares of Prenetics Global in a research report on Thursday, August 27th. They issued a “buy” rating and a $37.00 price objective on the stock. Wall Street Zen raised shares of Prenetics Global from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research note on Friday, July 17th. Finally, Benchmark increased their target price on Prenetics Global from $30.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 15th.

Get Prenetics Global alerts:

Read Our Latest Research Report on Prenetics Global

Insider Activity

In other Prenetics Global news, CFO Brian Rosin acquired 18,000 shares of the stock in a transaction dated Monday, August 24th. The stock was acquired at an average cost of $21.19 per share, with a total value of $381,420.00. Following the transaction, the chief financial officer owned 18,000 shares in the company, valued at $381,420. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Danny Sheng Wu Yeung acquired 17,181 shares of the company’s stock in a transaction dated Monday, August 24th. The stock was acquired at an average price of $21.23 per share, for a total transaction of $364,752.63. Following the acquisition, the chief executive officer owned 112,416 shares in the company, valued at approximately $2,386,591.68. The trade was a 18.04% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have bought 47,781 shares of company stock valued at $999,778.

Hedge Funds Weigh In On Prenetics Global

Several hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new stake in Prenetics Global during the fourth quarter worth approximately $1,302,000. 683 Capital Management LLC acquired a new position in shares of Prenetics Global in the 4th quarter valued at $1,181,000. Millennium Management LLC purchased a new position in shares of Prenetics Global in the 4th quarter valued at $810,000. Marshall Wace LLP purchased a new position in shares of Prenetics Global in the 4th quarter valued at $788,000. Finally, UBS Group AG raised its stake in Prenetics Global by 581.9% during the 3rd quarter. UBS Group AG now owns 46,561 shares of the company’s stock worth $619,000 after acquiring an additional 39,733 shares in the last quarter. 25.01% of the stock is currently owned by hedge funds and other institutional investors.

Prenetics Global Stock Performance

Shares of PRE opened at $25.44 on Monday. Prenetics Global has a 1 year low of $7.90 and a 1 year high of $27.24. The stock has a market capitalization of $429.17 million, a PE ratio of -6.12 and a beta of 0.31. The stock has a 50-day simple moving average of $20.08 and a 200-day simple moving average of $19.22.

Prenetics Global (NASDAQ:PRE – Get Free Report) last released its earnings results on Wednesday, August 19th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.31. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. The firm had revenue of $46.49 million for the quarter, compared to analyst estimates of $49.85 million. Analysts predict that Prenetics Global will post -1.86 EPS for the current year.

About Prenetics Global

(Get Free Report)

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.

Featured Stories

• Five stocks we like better than Prenetics Global
• AI Token Costs Are Changing the Hardware vs. Software Debate
• 3 ETFs That Could Move as Rate Expectations Shift
• 3 Stocks With September Catalysts Investors Shouldn’t Ignore
• Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains

Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.